Inspira Technologies Oxy BHN (IINN) has released an update.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Inspira Technologies Oxy BHN Ltd. has announced its intention to report clinical results for its innovative HYLA™ blood sensor in the fourth quarter of 2024, targeting the $2.5 billion Point of Care and ABG analyzer market. The HYLA™ sensor, which enables real-time monitoring of blood parameters during open-heart surgery, is a key part of Inspira’s long-term growth strategy and is expected to integrate with the FDA-cleared INSPIRA™ ART100 systems. Inspira is focusing on expanding its blood testing facilities and developing the HYLA™ sensor line to transform respiratory and life-support sectors, addressing a $59 billion annual market opportunity.
For further insights into IINN stock, check out TipRanks’ Stock Analysis page.